ASTCT Supports the FDA’s Accelerated Approval of AMTAGVI for Treatment of Metastatic Melanoma
CHICAGO, IL / ACCESSWIRE / February 19, 2024 / The American Society for Transplantation and Cellular Therapy® (ASTCT®) supports the...
Cancer
Poolbeg Pharma PLC Announces Director Share Purchase
LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on...
Medigene to Present at Upcoming Conferences
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on...
Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
ORION CORPORATION PRESS RELEASE 19 FEBRUARY 2024 at 13:15 EET Orion to investigate the possible outsourcing of its pharmaceutical production in...
Mdxhealth Announces Resignation of Board Member
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:...
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business OperationsCompany Targeting On or Before March 14,...
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain...
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”),...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add...
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative Diseases Can Be Delivered via Programmed Microglial CellsLONDON, UK / ACCESSWIRE...
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and...
Virtua Health partners with care.ai for enterprise-wide implementation of AI-Enabled Virtual Care Solutions for Patients
Virtua Health will leverage care.ai's Smart Care Facility Platform and Always-Aware ambient sensors to enhance patient care, support nursing staff,...
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning...
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for...
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will...
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company...
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...